Progyny, Inc. (NASDAQ:PGNY) Given Consensus Rating of “Moderate Buy” by Analysts

Posted by Brenda Bartman on May 24th, 2026

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $29.5455.

Several equities analysts have recently commented on the company. Citigroup reiterated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Canaccord Genuity Group upgraded Progyny from a “hold” rating to a “buy” rating and increased their price objective for the company from $19.00 to $30.00 in a research report on Tuesday. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. Finally, Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th.

Check Out Our Latest Stock Report on PGNY

Progyny Stock Up 0.8%

Shares of NASDAQ PGNY opened at $24.88 on Tuesday. The firm has a market capitalization of $1.95 billion, a P/E ratio of 32.31, a P/E/G ratio of 1.32 and a beta of 0.91. The stock’s 50-day simple moving average is $19.06 and its two-hundred day simple moving average is $22.03. Progyny has a twelve month low of $16.10 and a twelve month high of $28.75.

Progyny (NASDAQ:PGNY – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The company’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts anticipate that Progyny will post 1.12 EPS for the current fiscal year.

Insider Activity

In other news, CFO Mark S. Livingston sold 8,275 shares of the stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total transaction of $211,012.50. Following the transaction, the chief financial officer directly owned 79,063 shares in the company, valued at approximately $2,016,106.50. This represents a 9.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 4,657 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the transaction, the executive vice president owned 89,879 shares in the company, valued at $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 25,308 shares of company stock worth $579,977. 9.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Progyny

Several institutional investors have recently bought and sold shares of PGNY. Royal Bank of Canada boosted its holdings in Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares during the period. Amundi boosted its holdings in Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after acquiring an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after acquiring an additional 14,297 shares during the period. Invesco Ltd. boosted its holdings in Progyny by 37.4% during the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after acquiring an additional 103,253 shares during the period. Finally, Walleye Capital LLC boosted its holdings in Progyny by 6.9% during the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after acquiring an additional 780 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

About Progyny

(Get Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.